Vita Life Sciences Full Year 2023 Earnings: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Vita Life Sciences (ASX:VLS) Full Year 2023 Results

Key Financial Results

• Revenue: AU$74.2m (up 11% from FY 2022).
• Net income: AU$9.08m (up 28% from FY 2022).
• Profit margin: 12% (up from 11% in FY 2022). The increase in margin was driven by higher revenue.
• EPS: AU$0.17 (up from AU$0.13 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Vita Life Sciences shares are up 4.9% from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Vita Life Sciences, and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.